TY - JOUR
T1 - Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes
AU - Schmidt , Signe
AU - Frandsen, Christian S.
AU - Dejgaard, Thomas F.
AU - Vistisen, Dorte
AU - Halldorsson, Thorhallur
AU - Olsen, Sjúrður Fróði
AU - Jensen, Jens-Erik B.
AU - Madsbad, S.
AU - Andersen, Henrik
AU - Nørgaard, Kirsten
PY - 2021/9/30
Y1 - 2021/9/30
N2 - Aims: To present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump-treated type 1 diabetes (T1D), focusing on changes in body composition and dimensions, and to evaluate changes in food intake to identify potential dietary drivers of liraglutide-associated weight loss.Materials and methodsA 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects. For secondary outcome analysis, dual X-ray absorptiometry scans were completed at Weeks 0 and 26, and questionnaire-based food frequency recordings were obtained at Weeks 0, 13 and 26 to characterize liraglutide-induced changes in body composition and food intake.ResultsTotal fat and lean body mass decreased in liraglutide-treated participants (fat mass -4.6 kg [95% confidence interval {CI} -5.7; -3.5], P ConclusionsLiraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide- and placebo-treated participants.
AB - Aims: To present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump-treated type 1 diabetes (T1D), focusing on changes in body composition and dimensions, and to evaluate changes in food intake to identify potential dietary drivers of liraglutide-associated weight loss.Materials and methodsA 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects. For secondary outcome analysis, dual X-ray absorptiometry scans were completed at Weeks 0 and 26, and questionnaire-based food frequency recordings were obtained at Weeks 0, 13 and 26 to characterize liraglutide-induced changes in body composition and food intake.ResultsTotal fat and lean body mass decreased in liraglutide-treated participants (fat mass -4.6 kg [95% confidence interval {CI} -5.7; -3.5], P ConclusionsLiraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide- and placebo-treated participants.
KW - body composition
KW - food frequency
KW - insulin pump therapy
KW - liraglutide
KW - type 1 diabetes
KW - weight loss
U2 - 10.1111/dom.14567
DO - 10.1111/dom.14567
M3 - Article
C2 - 34595827
SN - 1463-1326
VL - 24
SP - 212
EP - 220
JO - Diabetes, obesity and metabolism
JF - Diabetes, obesity and metabolism
IS - 2
ER -
